Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
[1] A separate analysis by Walker et al
2014 Oct 1;62(39):9499-506
Side-by-Side Comparison How the Mechanisms Differ in Practice AOD-9604 targets the fat cell itself
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Some protocols extend beyond eight weeks depending on the severity of the condition and the patients response
US$ 20.58
US$ 24.02
US$ 24.64
US$ 25.58
US$ 20.37
US$ 27.12
US$ 24.91
